Trial Profile
Pilot Study Assessing the Safety and Tolerability of the Neoadjuvant Use of Tremelimumab (Anti-CTLA-4) Plus Durvalumab (MEDI4736) (Anti-PD-L1) in the Treatment of Resectable Colorectal Cancer Liver Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Adverse reactions
- 30 Jan 2023 Status changed from active, no longer recruiting to completed.
- 08 Mar 2022 Planned End Date changed from 30 Jul 2021 to 31 Dec 2022.
- 08 Mar 2022 Planned primary completion date changed from 30 Jul 2021 to 31 Dec 2022.